Danish drugmaker Novo Nordisk faces a class action lawsuit in New York. The company is accused of using its patents to keep a monopoly on its diabetes drug Victoza. A drug wholesaler claims Novo engaged in a pay-for-delay scheme with Teva Pharmaceutical. This allegedly delayed cheaper generic versions of Victoza. The lawsuit seeks unspecified monetary damages for Victoza purchasers.
